BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
REMS-Required Training And Certification Under Way
Executive Summary
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
You may also be interested in...
Bluebird Spinoff 2seventy Bio Gets Its Own Wings
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
Working Toward A Cure: Janssen’s Multiple Myeloma Strategy
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.